- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback